Next Generation Cardiometabolic Diagnostics

Zora Biosciences Oy is a diagnostic company with a cardiometabolic focus.

We use mass spectrometry to identify markers of disease and develop them into robust, high-throughput, value-added clinical diagnostic tests which are commercialized together with our international partners or through our own reference laboratory in Finland.

Our Diagnostic Tests

1) Heart disease: CERT2 - Ceramide-based cardiovascular risk score for assessing risk of myocardial infarction, cardiovascular death and stroke

2) Type 2 Diabetes: dSCORE - Ceramide-based risk score for the probability of type II diabetes onset

3) Fatty Liver Disease: In development

12.11.2026

New Study Presented at AHA 2026 Highlights CERT2 is lowered significantly by PCSK9-inhibitor treatment

Results from the ODYSSEY OUTCOMES trial show that CERT2 predicts cardiovascular events and mortality after acute coronary syndrome, while PCSK9 inhibition with alirocumab significantly reduces CERT2 scores.

Zora publications

Please check our latest publications including our research on coronary event risk. The publications can be found from News - Publications.

Publications